143 related articles for article (PubMed ID: 33128104)
21. Clinical and Striatal Dopamine Transporter Predictors of Mild Behavioral Impairment in Drug-Naive Parkinson Disease.
Yoo HS; Lee S; Chung SJ; Ye BS; Sohn YH; Yun M; Lee PH
Clin Nucl Med; 2020 Nov; 45(11):e463-e468. PubMed ID: 32956117
[TBL] [Abstract][Full Text] [Related]
22. Correlation of Parkinson disease severity and 18F-DTBZ positron emission tomography.
Hsiao IT; Weng YH; Hsieh CJ; Lin WY; Wey SP; Kung MP; Yen TC; Lu CS; Lin KJ
JAMA Neurol; 2014 Jun; 71(6):758-66. PubMed ID: 24756323
[TBL] [Abstract][Full Text] [Related]
23. Effect of striatal dopamine depletion on cognition in de novo Parkinson's disease.
Chung SJ; Yoo HS; Oh JS; Kim JS; Ye BS; Sohn YH; Lee PH
Parkinsonism Relat Disord; 2018 Jun; 51():43-48. PubMed ID: 29526657
[TBL] [Abstract][Full Text] [Related]
24. Nigrostriatal dopamine transporter availability in early Parkinson's disease.
Fazio P; Svenningsson P; Cselényi Z; Halldin C; Farde L; Varrone A
Mov Disord; 2018 Apr; 33(4):592-599. PubMed ID: 29436751
[TBL] [Abstract][Full Text] [Related]
25. Apathy and striatal dopamine transporter levels in de-novo, untreated Parkinson's disease patients.
Santangelo G; Vitale C; Picillo M; Cuoco S; Moccia M; Pezzella D; Erro R; Longo K; Vicidomini C; Pellecchia MT; Amboni M; Brunetti A; Salvatore M; Barone P; Pappatà S
Parkinsonism Relat Disord; 2015 May; 21(5):489-93. PubMed ID: 25753457
[TBL] [Abstract][Full Text] [Related]
26. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease.
Weintraub D; Newberg AB; Cary MS; Siderowf AD; Moberg PJ; Kleiner-Fisman G; Duda JE; Stern MB; Mozley D; Katz IR
J Nucl Med; 2005 Feb; 46(2):227-32. PubMed ID: 15695780
[TBL] [Abstract][Full Text] [Related]
27. 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease.
Koros C; Simitsi A; Prentakis A; Beratis I; Papadimitriou D; Kontaxopoulou D; Fragkiadaki S; Papagiannakis N; Seibyl J; Marek K; Papageorgiou SG; Trapali XG; Stamelou M; Stefanis L
Mov Disord; 2018 Nov; 33(11):1734-1739. PubMed ID: 30288781
[TBL] [Abstract][Full Text] [Related]
28. Altered striatal circuits underlie characteristic personality traits in Parkinson's disease.
Ishii T; Sawamoto N; Tabu H; Kawashima H; Okada T; Togashi K; Takahashi R; Fukuyama H
J Neurol; 2016 Sep; 263(9):1828-39. PubMed ID: 27334907
[TBL] [Abstract][Full Text] [Related]
29. Is the cingulate island sign a marker for early dementia conversion in Parkinson's disease?
Chung SJ; Kim SH; Park CW; Lee HS; Kim YJ; Lee PH; Jeong Y; Sohn YH
Eur J Neurol; 2023 Dec; 30(12):3732-3740. PubMed ID: 37505994
[TBL] [Abstract][Full Text] [Related]
30. Clinical and striatal dopamine transporter predictors of β-amyloid in dementia with Lewy bodies.
Yoo HS; Lee S; Chung SJ; Lee YH; Ye BS; Sohn YH; Yun M; Lee PH
Neurology; 2020 Mar; 94(13):e1344-e1352. PubMed ID: 32086384
[TBL] [Abstract][Full Text] [Related]
31. Optimal scanning time window for 18F-FP-(+)-DTBZ (18F-AV-133) summed uptake measurements.
Lin KJ; Lin WY; Hsieh CJ; Weng YH; Wey SP; Lu CS; Skovronsky D; Yen TC; Chang CJ; Kung MP; Hsiao IT
Nucl Med Biol; 2011 Nov; 38(8):1149-55. PubMed ID: 21831650
[TBL] [Abstract][Full Text] [Related]
32. Striatal dopamine transporter imaging correlates with depressive symptoms and tower of London task performance in Parkinson's disease.
Rektorova I; Srovnalova H; Kubikova R; Prasek J
Mov Disord; 2008 Aug; 23(11):1580-7. PubMed ID: 18618663
[TBL] [Abstract][Full Text] [Related]
33. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET.
Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P
Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023
[TBL] [Abstract][Full Text] [Related]
34. Anxiety is associated with striatal dopamine transporter availability in newly diagnosed untreated Parkinson's disease patients.
Erro R; Pappatà S; Amboni M; Vicidomini C; Longo K; Santangelo G; Picillo M; Vitale C; Moccia M; Giordano F; Brunetti A; Pellecchia MT; Salvatore M; Barone P
Parkinsonism Relat Disord; 2012 Nov; 18(9):1034-8. PubMed ID: 22789824
[TBL] [Abstract][Full Text] [Related]
35. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
[TBL] [Abstract][Full Text] [Related]
36. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress.
Aarsland D; Brønnick K; Ehrt U; De Deyn PP; Tekin S; Emre M; Cummings JL
J Neurol Neurosurg Psychiatry; 2007 Jan; 78(1):36-42. PubMed ID: 16820421
[TBL] [Abstract][Full Text] [Related]
37. Precise Evaluation of Striatal Oxidative Stress Corrected for Severity of Dopaminergic Neuronal Degeneration in Patients with Parkinson's Disease: A Study with 62Cu-ATSM PET and 123I-FP-CIT SPECT.
Neishi H; Ikawa M; Okazawa H; Tsujikawa T; Arishima H; Kikuta KI; Yoneda M
Eur Neurol; 2017; 78(3-4):161-168. PubMed ID: 28848099
[TBL] [Abstract][Full Text] [Related]
38. Correlating Parkinson's disease motor symptoms with three-dimensional [(18)F]FP-CIT PET.
Chung M; Park YS; Kim JS; Kim YJ; Ma HI; Jang SJ; Huh R; Kim HS; Kim WC
Jpn J Radiol; 2015 Oct; 33(10):609-18. PubMed ID: 25952404
[TBL] [Abstract][Full Text] [Related]
39. In vivo detection of monoaminergic degeneration in early Parkinson disease by (18)F-9-fluoropropyl-(+)-dihydrotetrabenzazine PET.
Lin SC; Lin KJ; Hsiao IT; Hsieh CJ; Lin WY; Lu CS; Wey SP; Yen TC; Kung MP; Weng YH
J Nucl Med; 2014 Jan; 55(1):73-9. PubMed ID: 24287322
[TBL] [Abstract][Full Text] [Related]
40. Regional changes in the type 1 cannabinoid receptor are associated with cognitive dysfunction in Parkinson's disease.
Ceccarini J; Casteels C; Ahmad R; Crabbé M; Van de Vliet L; Vanhaute H; Vandenbulcke M; Vandenberghe W; Van Laere K
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2348-2357. PubMed ID: 31342135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
